Press Release Gothenburg, June 04, 2003

Cellectricon receives U.S. approval for pioneering patent that reveals the inner secrets of cells

The Swedish biotech tools company Cellectricon today announced U.S. approval of pioneering patent (U.S. Patent #6,521,430) covering methods for accessing the inner world of cells using transient membrane permeabilization. The approved patent is of central importance to the commercialization of Cellectricon's high-throughput platforms for novel drug targets. The pharmaceutical and biotechnology industries are the primary target groups for the technology, which provides new high-throughput capabilities in drug discovery.

Owe Orwar, Professor and Co-founder of Cellectricon says: "Cellectricon is extremely pleased to be in the forefront in the development of this wide-ranging technology, which reveals the inner secrets of cells and allows new avenues in drug development". Jakob Lindberg, Cellectricon's CEO, adds: "The electroporation patent family strengthens Cellectricon's already extensive patent portfolio and gives us a highly competitive position in the biotech market".

Cellectricon's patented invention provides a novel, highly spatially resolved technique to alter the biochemical content of cells based on permeabilization of phospholipid bilayer membranes by pulsed electric fields, *i.e.* so called electroporation. The method may be used to transfer cell-membrane-impermeant solutes, such as molecular probes, drugs, DNA, and RNA, as well as antisense oligonucleotides and agents for RNAi sensing into cell structures. The method facilitates rapid whole-proteome screening targeting specific intracellular proteins and their characterization as potential targets for different drug therapies. For further information see Editors Note and image below.

About Cellectricon AB

Cellectricon is a Swedish biotechnology tools company that develops microfabricated cell-based tools for the pharmaceutical and biotechnology industries. Cellectricon works at the microtechnology and biology interface inventing products that will allow productivity increases primarily in the drug discovery process. The company was formed based on an extensive and solid patent portfolio within different areas such as high-throughput electrophysiology, patch-clamp, microfluidics, microfabrication, and electroporation. The first product generation, DynaflowTM, focuses on chip-based platforms for drug screening applications. The DynaflowTM technology is built around a ground-breaking microfluidic device offering higher-throughput screening for drugs targeting ion channels. Cellectricon is currently owned by Investor Growth Capital, Innovationskapital and the Karolinska Investment Fund, together with employees and seed investors.

Editors Note:

The inner world of cells is an enclosed, protected and well-defined chemical environment. In this tiny space, 90% of the cells biologically active structures, such as receptors and various proteins, are located. Many of these are potential targets for

Cellectricon, Fabriksgatan 7, SE-412 50 Göteborg, Sweden.
Phone: +46 (0)760 35 00. Fax: +46 (0)31 40 42 80. Email: info@cellectricon.se Internet: www.cellectricon.se

different drug therapies. However, it is a major challenge to introduce compounds into the cell. Cellectricon's patented technology facilitates the access to this world –by exposing cells to transient electric fields, small holes are formed in the cell membrane, enabling introduction of various compounds ranging from small molecules to genes and proteins. This technology is highly interesting for a broad targets located inside the boundary of cell.



With Cellectricons patented electroporation technology, minaturized electrodes are utilized to form tiny holes in the membrane of cells, facilitating the introduction of cell-impermeable solutes into the cellular environment.

For further information, visit www.cellectricon.se or contact:

Jakob Lindberg, CEO

Tel: +46 (0) 31 760 35 02
Mobile: +46 (0)70 569 54 71
Email: jakob.lindberg@cellectricon.se

Owe Orwar, CSO

Tel: +46 (0) 31 760 35 07
Mobile: +46 (0)70 299 29 89
Email: orwar@phc.chalmers.se

Susanne Orwar, Communications Manager

Tel: +46 (0) 31 760 35 15
Mobile: +46 (0)733 67 35 15
Email: susanne.orwar@cellectricon.se